DoW Vision, Clinical Trial Award
Open Posted
- Opportunity number
- HT942526VRPCTA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Department of Army Medical Command is soliciting applications for the Fiscal Year 2026 Vision Research Program Clinical Trial Award, supporting rapid implementation of clinical trials addressing service-connected eye injury and visual dysfunction, with full applications due November 12, 2026. Applicants must have an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application (or equivalent) submitted to the relevant Regulatory Agency by the application deadline, with documentation of active/safe-to-proceed status required by March 1, 2027, to be considered for funding.
Eligibility extends unrestricted to extramural and intramural U.S. Department of War organizations, including foreign and domestic entities, for-profit and nonprofit organizations. Independent investigators regardless of ethnicity, nationality, or citizenship status may serve as Principal Investigator. Research must align with at least one of three focus areas: understanding and treating eye injury or visual dysfunction related to military exposure; diagnosing and treating eye injuries in austere environments; or restoring visual function after military exposure-related vision loss.
The award ceiling is $2.6 million per application over a maximum period of performance of three years. One Clinical Trial Award is expected to be funded. Applications undergo two-tiered review: peer review assesses Clinical Impact, Research Strategy and Feasibility, Recruitment/Accrual/Retention, Regulatory Strategy and Transition Plan, Statistical Plan and Data Analysis, Ethical Considerations, and Personnel and Communication; programmatic review evaluates adherence to award intent, contribution to program portfolio, and relative impact and relevance to military health.
Pre-applications are due July 28, 2026 at 5:00 p.m. Eastern time through eBRAP. Full applications are due November 12, 2026 at 11:59 p.m. Eastern time through Grants.gov (extramural organizations) or eBRAP (intramural DOW organizations). Peer review is scheduled for January 2027 and programmatic review for March 2027, with awards expected by September 30, 2027.
The opportunity is funded under the Military Medical Research and Development program (CFDA 12.420).
Synopsis
Summary: The fiscal year 2026 (FY26) Vision Research Program (VRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of service-connected eye injury and visual dysfunction. Research must align with at least one of the FY26 VRP Focus Areas.
Distinctive Features:
· For interventions that require Investigational New Drug (IND)/Investigational Device Exemption (IDE) or equivalent regulatory authorizations for clinical testing, the IND/IDE application or equivalent must be submitted to the relevant Regulatory Agency by the CTA application submission deadline. In addition, applicants must provide documentation of communication from the Regulatory Agency indicating that the IND/IDE or equivalent is active/safe to proceed by March 1, 2027, in order for the CTA application to be considered for funding.Refer to Attachment 7: Regulatory Strategy for further details.
· Scored peer review criteria include Clinical Impact; Research Strategy and Feasibility; Recruitment, Accrual, Retention; Regulatory Strategy and Transition Plan; Statistical Plan and Data Analysis; Ethical Considerations; Personnel and Communication.
· Programmatic review criteria include adherence to the intent of the CTA, contribution to program portfolio, relative impact and relevance to military health.
https://cdmrp.health.mil/pubs/press/2026/vrppreann
Files
| File | Type | Posted |
|---|---|---|
| HT942526VRPCTA_GG.pdf | ||
| PKG00292665.pdf | ||
| FY2026 VRP PA Reference Table_Final.pdf | ||
| HT942526VRPCTA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity